Kiadis Pharma N.V.
Please note: The information displayed on this page might be outdated.
Kiadis Pharma N.V.:
NK-cell platform administered as adjunct I-O on top of HSCT. High-dose potent NK cells expanded/activated w patented PM21 nanoparticles. Launched FIH POC trial in r/r AML patients (Feb 2020); set to launch additional HSCT trial later in 2020 w/interim data exp 2021. Presenting new data on ex-vivo FC21 expanded NK-cell therapy in 13 patients at EBMT in 2020. Established POC in 37 patients total.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe, US - New England
Clinical Stage
Phase III, Phase l or ll, Pre-Clinical Stage
Disease Space
Hematology, Immunotherapy, Oncology
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Public
Market Cap
<100MM
Therapeutic Modalities
Cell Therapy
Website:
Address:
Boston
Boston, MA
United States
Boston, MA
United States
More info:
My account:
Company Participants at European Biotech Investor Days 2021
Arthur Lahr
Kiadis Pharma N.V., CEO
Arthur Lahr is Chief Executive Officer of Kiadis Pharma. Prior to joining Kiadis Pharma, he was Chief Strategy Officer and member of the Management Committee at Crucell from 2001 until its acquisition by Johnson & Johnson in 2011. Before that he was consultant at McKinsey & Company and engineer at Unilever. At present, Mr. Lahr also serves as a member of the supervisory board of Sanquin, the Dutch national plasma and blood product supplier. Mr. Lahr holds a Masters degree in Applied Physics from the University of Delft, The Netherlands, and an MBA from INSEAD, France.
Upcoming Company Event Participation
European Biotech Investor Days 2021
Virtual,
April 7 –
April 8, 2021
Top 10 Holders of Kiadis Pharma NV
| Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
|---|---|---|---|---|---|
| Pentwater Capital Management LP | 13.09 | 3,871,327 | 0.00 | Stakes | 2/18/21 |
| UBS Asset Management Switzerland AG | 10.01 | 2,958,882 | 0.00 | Stakes | 12/3/20 |
| Empery Asset Management LP | 6.60 | 1,950,779 | 0.00 | Stakes | 9/1/20 |
| Carlson Capital LP | 4.11 | 1,216,223 | 0.00 | Stakes | 1/7/21 |
| LSP Advisory BV | 3.76 | 1,515,079 | 0.00 | Funds | 6/30/20 |
| GLG Partners LP | 0.40 | 118,435 | 0.00 | Stakes | 2/16/21 |
| BNP Paribas Asset Management Belgium SA | 0.40 | 116,931 | 0.00 | Funds | 12/31/20 |
| GAM Investment Management (Switzerland) AG (Lugano Branch) | 0.24 | 69,766 | 0.00 | Funds | 12/31/20 |
| BNP Paribas Asset Management France SAS | 0.10 | 41,691 | 0.00 | Funds | 6/30/20 |
| Bantleon Bank AG | 0.05 | 15,000 | 0.00 | Funds | 12/30/20 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.